The last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. While considerable advances have been reported, there is still a signi- cant amount of work left to accomplish before our ambitions can be achieved. It now seems timely to review the accomplishments achieved to date and to clarify the challenges that remain. The choice of radionuclide, the conjugation p- cedure employed, and the selection of suitable targets were early issues that were faced by our field that still persist, however we can now tackle these obstacles with significantly better insight. The expanding array of new targeting molecules (recombinant antibodies, peptides and agents based upon alternate scaffolds) may increase the therapeutic efficacy or even modify the radiation sensitivity of the targeted tumor cell. The title of this book "Targeted Radionuclide Tumour Therapy - Biological Aspects" was selected to reinforce the concept that a major focus of this volume was devoted to understanding the biological effects of targeting and radiation. These important issues have not previously been the primary focus in this context. Furthermore, our rapidly expanding knowledge of different types of cell death and the increasingly likely existence of cancer stem cells suggests to us that even more efficient approaches in targeting might be possible in the future.

This book would combine chapters written by the most qualified authors around the world whose research encompasses the effect of morphine or other opioids on tumor growth and metastasis. This includes clinicians involved in trials determining which type of post surgical pain management can minimize the risk of recurrence or metastasis, researchers working on animal models and studying the effect of morphine on tumors, and most importantly the mechanism for this effect, and lastly cell biologists. There is currently a lot of research going on trying to reconcile the pro- and anti-cancer aspects of opioids actions.

These proceedings contain the papers selected for presentation at the 23rd Inter- tional Information Security Conference (SEC 2008), co-located with IFIP World Computer Congress (WCC 2008), September 8-10, 2008 in Milan, Italy. In - sponse to the call for papers, 143 papers were submitted to the conference. All - pers were evaluated on the basis of their signi?cance, novelty, and technical quality, and reviewed by at least three members of the program committee. Reviewing was blind meaning that the authors were not told which committee members reviewed which papers. The program committee meeting was held electronically, holding - tensive discussion over a period of three weeks. Of the papers submitted, 42 full papers and 11 short papers were selected for presentation at the conference. A conference like this just does not happen; it depends on the volunteer efforts of a host of individuals. There is a long list of people who volunteered their time and energy to put together the conference and who deserve acknowledgment. We thank all members of the program committee and the external reviewers for their hard work in the paper evaluation. Due to the large number of submissions, p- gram committee members were required to complete their reviews in a short time frame. We are especially thankful to them for the commitment they showed with their active participation in the electronic discussion

"Advances in Cancer Research" provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics, including nitric oxide-induced apoptosis in tumor cells, detection of minimal residual disease, immunity to oncogenetic human papillomavirus, and modeling prostate cancer in the mouse.

This unique, research-based investigation of the U.S. breast cancer movement compares the "pink" and "green" efforts within the movement and documents their use of similar citizen-science alliances, despite the contention over the use of consumer-based activism and pink products. Breast cancer activism is one of the most flourishing research and health advocacy movements in U.S. history. Yet the incidence of breast cancer is continuing to increase. This critical and revealing text investigates breast cancer activism in its two forms-the "pink movement" that focuses on developing awareness of, coping with, and managing breast cancer; and the "green movement" that strives to determine the possible environmental causes of breast cancer-such as pesticides, chemicals, and water and air pollution-and thereby hopes to prevent breast cancer. What caused this new green movement to develop? Will it replace or merge with the pink movement? Does either approach offer more promise for a solution? And how do the two movements differ in their positions or methodology towards a similar goal? With information culled from interviews with more than 50 industry stakeholders, The Green Solution to Breast Cancer: A Promise for Prevention argues that key attributes such as strategy, mission, and branding have led to a greater convergence between the pink and green wings of the movement and presents information that enables readers to consider if either approach might be the shorter route to beating breast cancer. Examines research findings that suggest that the pink and green aspects of the breast cancer movement are no longer separate but in fact are converging towards a focus on environmental prevention Provides an in-depth examination of advocacy organizations and the ways in which an organization's structure and ideology shape its agenda and strategies Looks critically at controversial aspects of the consumerism of the pink movement, the small portion of sales actually given to cancer research, and other shortcomings of this attempt to shop our way out of a nonetheless still-increasing disease Presents valuable information for upper level undergraduate and graduate students in political science within American politics or health politics courses as well as those studying women's and gender studies, sociology, nursing, and non-profit enterprises

Cancer is one of the leading killers in the world and the incidence is increasing, but most cancer patients and cancer survivors suffer much from the disease and its conventional treatments' side effects. In the past, clinical data showed that some complementary and alternative medicine (CAM) possessed anticancer abilities, but some clinicians and scientists have queried about the scientific validity of CAM due to the lack of scientific evidence. There is great demand in the knowledge gap to explore the scientific and evidence-based knowledge of CAM in the anticancer field. With this aim, a book series is needed to structurally deliver the knowledge to readers. There have been a number of publications on materia medica for various cancers in recent years, the scientific and medical community are thrust for up-to-date information that are supported by concrete laboratory evidences or clinical trials. This volume is a specialised book presenting the experimental and clinical evidences of anticancer materia medica for various cancers. This book consists of sixteen chapters, providing concise reviews and expert opinions on the recent progress of materia medica research in fourteen particular cancers from bench to bedside application. In addition, the book also includes a chapter with an overview of evidence-based materia medica for cancer chemoprevention, as well as a chapter discussing on the pharmacokinetics of anticancer materia medica. Gathering international opinion leaders' views, this volume will contribute great to the cancer, academic, and clinical community by providing evidence-based information on the anticancer effects of materia medica for various cancers. Readership Oncologists, cancer researchers, pharmacologists, pharmaceutical specialists, Chinese medicine practitioners, medical educators, postgraduates and advanced undergraduates in biomedical disciplines, cancer caregivers, cancer patients.

Low- and middle-income countries have seen a dramatic rise in the incidence of breast and gynecological cancers in the past decade. Organized cancer screening programs are not widely available in developing countries, leading to disproportionately higher mortality rates compared to those in the developed world. This book addresses cost-effective strategies for implementing programs aimed at screening for the early detection of breast, cervical, endometrial, and ovarian cancers. A well woman clinic concept providing such services as part of women's health examinations is proposed, aiming to ensure patient compliance by limiting clinic visits required for initial testing and diagnosis of screen positive cases.

This work provides a state-of-the art overview on the most relevant aspects of cell polarity. Volume 1 addresses cell polarity and cell migration (front-rear polarity), cell polarity and barrier formation (apico-basal polarity) and neuronal polarity. It particularly focuses on cell polarity at the molecular level and the underlying molecular mechanisms. It also elaborates the common principles and mechanisms that regulate cellular polarization in different cell types and contexts. Both volumes are intended for professors, group leaders and researchers in cell biology as well as medical professionals in the fields of anatomy, cell biology, physiology, pathology and tumor biology.

The second edition of this book serves both as an introductory and reference book focusing on the field of metastatic bone disease. Featuring contributions from experts in the field, this volume describes the molecular and cellular mechanisms involved in the formation of bone metastases, presents the newer advances made in the understanding of the clinical picture and symptoms of patients, analyses the role of bone markers in research and clinical practice and deals with all aspects of imaging modalities applied for the detection and evaluation of bone metastases. Moreover, the use of all available treatment methods, such as radiotherapy, surgery and systemic treatments for the management of patients with metastatic bone disease is discussed in detail. Overall this volume presents a thorough overview of all aspects of metastatic bone disease and provides a comprehensive and concise information resource for researchers, oncologists, orthopaedic surgeons and clinicians dealing with patients with metastatic bone disease.

Proposed topics for this issue include: Malignant Masquerade: Dilemmas in Diagnosing Biliary Obstruction; Molecular Mechanisms of Cholangiocarcinogenesis; Multimodality Imaging of Biliary Malignancies; Percutaneous Approach to the Diagnosis and Treatment of Biliary Tract Malignancies; Portal Vein Embolization in Hilar Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma: Current surgical strategy; Management and Extent of Resection for Intrahepatic Cholangiocarcinoma; Surgical Management of Gallbladder Cancer; Transplantation for Cholangiocarcinoma: When and for Whom?; Radical Resection of Biliary Tract Cancers and the Role of Extended Lymphadenectomy; Indications for neoadjuvant, adjuvant and palliative chemotherapy in the treatment of biliary tract cancers.

Triazenes: Synthesis and Chemical Properties.- Mechanisms of the Biological Actions of Triazenes.- Triazenes and Triazene N-Oxides: Antitumour Action in Animal Tumour Systems.- Antimestastatic Action of Triazene Derivatives.- Effects of Triazenes on Immune Responses.- Xenogenization of Experimental Tumors by Triazene Derivatives.- The Metabolism of Antineoplastic Triazenes.- Notes on the Metabolism, Pharmacokinetics and Mode of Action of N-Methyl and N-Ethyl-Triazenes in Relation to Their Pharmacological Activity.- Clinical Use of Triazenes.- Clinical Studies with the p-Carboxyl-Dimethyl-Phenyl-Triazene CB10-277.- Triazenes: Therapeutic Considerations and Perspectives.- Antitumor Imidazotetrazines: Prodrugs Targeted to the Major Groove of DNA.- O6-Alkylguanine-DNA-Alkyltransferase Gene Expression and the Cytotoxicity of Triazenes.- N-Methylmelamines, a Unique Class of Anti-Tumour Agents?.- Experimental Background and Early Clinical Studies with Imidazotetrazine Derivatives.- 'O6-Alkylguanine-DNA-Alkyltransferase: Significance, Methods of Measurement and Some Human Tumor and Normal Tissue Levels' (Contributions of the Workshop).- Summary of Poster-Sessions.- Contributors.

DNA Tumor Viruses will focus on the DNA viruses in the human population that are associated with cancers. It will cover most of the viruses that are thought to contribute to human malignancy.

This book will represent a comprehensive review of the field of DNA tumor virology. Right now, while there are books out there that cover individual viruses that will be also covered in this book, there is no single book that covers this topic comprehensively.

The main textbook in this market, Fields, which is referred to by both reviewers, covers some of these topics but on a lower level. The only two books that are nearly as comprehensive as this one are Human Tumor Viruses, which was published by the American Society for Microbiology in 1998 and is quite outdated, and Viruses, Cell Transformation, and Cancer, which was published by Elsevier in 2001. Our book will be the only current, comprehensive review of its kind in the market.

This book focuses on the prophylactic potential of diet-derived factors in primary prevention of cancer. It is written by a group of highly reputed experts in the area of dietary agents and cancer chemoprevention. The translational potential of dietary factors from epidemiological, laboratory and clinical studies as prevention strategy in normal and risk populations is highlighted. The work presents options of routine inclusion of specific dietary regimens for prevention as well as therapeutic strategy for better management through adjuvant interventions in cancer treatment.

Contents: Gerard Jaouen, Nils Metzler-Nolte : Introduction ; Stephane GIBAUD and Gerard JAOUEN: Arsenic - based drugs: from Fowler's solution to modern anticancer chemotherapy; Ana M. Pizarro, Abraha Habtemariam and Peter J. Sadler : Activation Mechanisms for Organometallic Anticancer Complexes; Angela Casini, Christian G. Hartinger, Alexey A. Nazarov, Paul J. Dyson : Organometallic antitumour agents with alternative modes of action; Elizabeth A. Hillard, Anne Vessieres, Gerard Jaouen : Ferrocene functionalized endocrine modulators for the treatment of cancer; Megan Hogan and Matthias Tacke : Titanocenes - Cytotoxic and Anti-Angiogenic Chemotherapy Against Advanced Renal-Cell Cancer; Seann P. Mulcahy and Eric Meggers : Organometallics as Structural Scaffolds for Enzyme Inhibitor Design; Christophe Biot and Daniel Dive : Bioorganometallic Chemistry and Malaria; Nils Metzler-Nolte : Biomedical applications of organometal-peptide conjugates; Roger Alberto : Organometallic Radiopharmaceuticals; Brian E. Mann : Carbon Monoxide - an essential signaling molecule.

Updated and expanded, this Second Edition of Essentials of Clinical Radiation Oncology continues to provide a succinct and effective review of the most important studies in the field. Organized by disease topic and grouped by body part, each chapter employs structured sections for targeted information retrieval and retention. Chapters begin with a "Quick Hit" overview of each disease summarizing the most significant paradigms before moving into dedicated summaries on epidemiology, risk factors, anatomy, pathology, genetics, screening, clinical presentation, workup, prognostic factors, staging, treatment paradigm, and medical management. An evidence-based question and answer section concludes each chapter, which pairs commonly encountered clinical questions with answers connecting historical context and pertinent clinical studies to better inform decision making and treatment planning.Providing the latest treatment paradigms and guidelines, this comprehensive second edition now outlines the evidence and must-know considerations for using radiation therapy with immunotherapy, the strategies for metastasis-directed therapy for oligometastatic disease, and much more. Written for the practicing radiation oncologist, related practitioner, and radiation oncology resident entering the field, this "one-stop" resource is the go-to reference for everyday practice. Key Features: Structured sections offer high-yield information for targeted review Cites need-to-know clinical studies and treatment guidelines in evidence-based question and answer format Each chapter has been reviewed and updated to include the most recent and relevant studies New chapters on spine tumors, thyroid cancer, sinonasal tumors, cholangiocarcinoma, renal cell carcinoma, multiple myeloma and plasmacytoma, miscellaneous pediatric tumors, and treatment of oligometastatic disease from underlying cancers Designed for quick reference with comprehensive tables on treatment options and patient selection, workup, and prognostic factors by disease site Purchase includes digital access for use on most mobile devices or computers

Hyaluronan biology is being recognized as an important regulator of cancer progression. Paradoxically, both hyaluronan (HA) and hyaluronidases, the enzymes that eliminate HA, have also been correlated with cancer progression. Hyaluronan, a long-chain polymer of the extracellular matrix, opens up tissue spaces through which cancer cells move and metastasize. It also confers motility upon cells through interactions of cell-surface HA with the cytoskeleton. Embryonic cells in the process of movement and proliferation use the same strategy. It is an example of how cancer cells have commandeered normal cellular processes for their own survival and spread. There are also parallels between cancer and wound healing, cancer occasionally being defined as a wound that does not heal.
The growing body of literature regarding this topic has recently progressed from describing the association of hyaluronan and hyaluronidase expression associated with different cancers, to understanding the mechanisms that drive tumor cell activation, proliferation, drug resistance, etc. No one source, however, discusses hyaluronan synthesis and catabolism, as well as the factors that regulate the balance. This book offers a comprehensive summary and cutting-edge insight into Hyaluronan biology, the role of the HA receptors, the hyaluronidase enzymes that degrade HA, as well as HA synthesis enzymes and their relationship to cancer.
* Offers a comprehensive summary and cutting-edge insight into Hyaluronan biology, the role of the HA receptors, the hyaluronidase enzymes that degrade HA, as well as HA synthesis enzymes and their relationship to cancer
* Chapters are written by the leading international authorities on this subject, from laboratories that focus on the investigation of hyaluronan in cancer initiation, progression, and dissemination
* Focuses on understanding the mechanisms that drive tumor cell activation, proliferation, and drug resistance

This project follows on the success of the book "25 years of p53", published by Springer in 2006. Since this publication, there have been considerable advances on the potential application of p53 into the clinics. The goal of this book is to capture these developments and to appeal to a clinical and medical audience beyond the one which was the primary target of "25 years of p53".

Population studies and epidemiology facilitate the discovery of genetic and environmental determinants of cancer and the development of new approaches to cancer control and prevention, therefore they play a central role in the creation of health policies. Cancer Epidemiology compiles areas of research which cover etiological factors or determinants that contribute to the development of cancer and describe the the latest technologies in cancer epidemiology. In Volume 2, Modifiable Factors, leading experts provide chapters on modifiable factors in cancer epidemiology, epidemiology of organ specific cancer, and environmental and life style factors. Although a non-standard volume of the highly successful Methods in Molecular Biology (TM) series, this comprehensive text retains the commitment of the series to collecting the kind of detailed, up-to-date information and implementation advice that is crucial for getting optimal results. Cutting-edge and essential, Cancer Epidemiology allows readers to get the maximum advantage of the methods involved in this exciting and important field.

DNA and RNA fractions have been isolated from the whole blood, serum, plasma, the surface of blood cells, urine, saliva and spinal fluid from both healthy individuals and clinical patients. Recent developments are presented concerning the isolation, quantification and analysis of these molecules and their use in the identification of specific nucleic acid fragments related to a variety of clinical disorders thereby permitting their early diagnosis and prognosis.

The purpose of this book is to examine the etiology of cancer in large human populations using mathematical models developed from an inter-disciplinary perspective of the population epidemiological, biodemographic, genetic and physiological basis of the mechanisms of cancer initiation and progression. In addition an investigation of how the basic mechanism of tumor initiation relates to general processes of senescence and to other major chronic diseases (e.g., heart disease and stroke) will be conducted.

This volume explores data from the applications of molecular biological methods and the applications of recent immunological and cytogenetic methods in Epstein-Barr Virus (EBV) that will offer readers possible new solutions to the unresolved problems in the EBV field. Chapters in this book cover topics such as: viral life cycle, latency, EBV-associated diseases and EBV diagnostics; in vitro methods including organotypic cultures for the analysis of EBV-epithelial cell interactions; identification of the interacting viral and cellular proteins using affinity purification-mass spectrometry methods; 3D telomere FISH; transcription analysis using high-throughput RNA sequencing, qPCR and nuclear run-on assay; analysis of viral and cellular microRNAs; isolation and characterization of exosomes and the assessment of their function; characterization of the viral genome by terminal repeat analysis and sequencing; the use of chromatin immunoprecipitation coupled sequencing (ChIP-Seq) for the analysis of Zta-DNA interactions; epigenetic analysis by bisulfite sequencing and ChIP; novel in vivo models for the study of EBV infection; and how immunological, virological, tissue culture and molecular methods can be combined to yield Good Manufacturing Practice-compliant EBV-specific T cells for the immunotherapy of EBV-associated post-transplant lymphoproliferative diseases (PTLD). Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and comprehensive, Epstein Barr-Virus: Methods and Protocols is a valuable resource for anyone who is interested in this fascinating and evolving field.

This book provides readers with an overview of the frequent occurrence of asymmetric cell division. Employing a broad range of examples, it highlights how this mode of cell division constitutes the basis of multicellular organism development and how its misregulation can lead to cancer. To underline such developmental correlations, readers will for example gain insights into stem cell fate and tumor growth. In turn, subsequent chapters include descriptions of asymmetric cell division from unicellular organisms to humans in both physiological and pathological conditions. The book also illustrates the importance of this process for evolution and our need to understand the background mechanisms, offering a valuable guide not only for students in the field of developmental biology but also for experienced researchers from neighboring fields.